Krystal Biotech, Inc. rose 3.58% in intraday trading, with Chardan trimming its price target on the company to $216. Krystal Biotech, Inc. is an integrated, commercial-stage biotechnology company focused on the discovery, development, and commercialization of genetic medicines to treat diseases with high unmet medical needs.
Comments
No comments yet